Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.
Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.
Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.
Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.
22nd Century Group advocates for FDA regulation of nicotine levels in cigarettes to reduce addiction and save lives. CEO James A. Mish emphasizes that lowering nicotine can lead to over 8 million fewer deaths by century’s end. The proposal aligns with the FDA's prior plans to combat smoking-related diseases, which result in over 480,000 deaths annually in the U.S., costing $300 billion in healthcare. The company urges Congress to support this vital public health initiative.
22nd Century Group (XXII) announced a significant expansion of its growing program for VLN® reduced nicotine tobacco for the 2021 crop year. This increase aligns with favorable sales projections and supports the expected launch of VLN® cigarettes, which contain 95% less nicotine than conventional brands. The company is awaiting the FDA's authorization of its Modified Risk Tobacco Product application. The new planting will create income for American family farmers and aims to capture a share of the U.S. tobacco market, potentially leading to substantial revenue growth.
22nd Century Group (NYSE American: XXII) announces the granting of a new U.S. patent that enables precise control over cannabinoid and terpene production in hemp/cannabis plants. This patent allows the company to genetically modify plants to optimize therapeutic qualities, reducing development time from 10-20 years to just 4-5 years. The technology is expected to increase cannabinoid yields and create tailored plant profiles for various applications, enhancing the company's competitive edge in the growing $100 billion hemp/cannabis market.
22nd Century Group (XXII) has received an order from the FDA for 3.6 million variable nicotine research cigarettes aimed at supporting studies for a national standard of minimally or non-addictive nicotine levels. The company's VLN® cigarettes, containing 95% less nicotine, are under FDA review for Modified Risk Tobacco Product (MRTP) designation, which is expected to be granted soon. The FDA's plan could save millions of lives, and 22nd Century aims to capitalize on this opportunity, potentially increasing its market capitalization significantly.
22nd Century Group, Inc. (NYSE American: XXII) announced its participation in the 13th Annual LD Micro Main Event Conference, scheduled for December 14, 2020, at 9:20 a.m. ET. CEO James A. Mish will present to a live virtual audience, allowing for a 10-minute Q&A session. The event will showcase a new format beneficial to both executives and investors. A live webcast of the presentation will be accessible on the company's website, with an archived replay available afterwards. This highlights the company's focus on tobacco harm reduction and hemp/cannabis research.
22nd Century Group, Inc. (NYSE American: XXII) is urging the FDA to expedite its Comprehensive Plan on Tobacco and Nicotine Regulation to mandate lower nicotine levels in cigarettes. The company highlights the urgent need for such reforms, citing that smoking causes nearly 500,000 deaths annually in the U.S. The ongoing COVID-19 pandemic emphasizes the critical importance of respiratory health. John Pritchard, the company's VP of regulatory science, stresses that products developed by 22nd Century can help reduce addiction and improve public health, yet authorization delays hinder their potential impact.
22nd Century Group will have its CEO, James A. Mish, participate in a panel at the Cowen 2020 Boston Cannabis Conference on December 2, 2020, focusing on innovations in tobacco and cannabis industries. The panel, moderated by Vivien Azer, will discuss the impact of the election, COVID-19, and current industry trends. One-on-one meetings with investors will occur from November 30 to December 2, 2020. The company aims to reduce smoking harm through reduced nicotine content tobacco products and advance hemp/cannabis research.
22nd Century Group (NYSE American: XXII) announced its participation in the Virtual Fall Investor Summit from November 16-18, 2020. The company will present on November 17 at 4:30 p.m. ET. Investors can access the live webcast and presentation through the Investors section of its website. The archived replay will be available after the event. 22nd Century focuses on tobacco harm reduction and hemp/cannabis research.
22nd Century Group (XXII) is committed to reducing smoking harm by securing Modified Risk Tobacco Product (MRTP) authorization from the FDA for its VLN® cigarette, which contains 95% less nicotine than major brands. The company plans to launch VLN® within 90 days of receiving authorization, supported by new patents improving genetic control over nicotine levels. Net sales rose 13.1% year-over-year to $7.3 million, with operating loss improving by $3.6 million. 22nd Century's cash position stands at $26.8 million, indicating strong liquidity for future operations.
22nd Century Group (NYSE American: XXII) will host a live audio webcast on November 5, 2020, at 8:00 a.m. EST to discuss its 2020 third quarter results, which will be released at 7:00 a.m. EST that day. CEO James A. Mish and other executives will outline a new strategic plan focusing on innovation, growth opportunities, and company re-alignment. A Q&A session will follow, allowing analysts and investors to interact directly. The webcast will be available on the Company’s Investor Relations page, with an archived replay accessible post-event.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
